Background: Although hypoglycemia is the most common complication of intensive diabetes therapy, there is little information about risk factors for hypoglycemia in patients with type 2 diabetes mellitus.
H
YPOGLYCEMIA is a significant complication of diabetes therapy. Although m i l d h y p o g l y c e m i a causes unpleasant symptoms and disrupts patients' daily activities, severe hypoglycemia can result in coma, seizures, and death. Moreover, recurrent episodes of mild hypoglycemia can alter the counterregulatory response to decreased blood glucose levels and lead to hypoglycemia unawareness, placing patients at increased risk for development of severe hypoglycemia. 1 Recurrent hypoglycemia has also been found to decrease quality of life in patients with diabetes. [2] [3] [4] Although hypoglycemia is well recognized as a problem in management of type 1 diabetes mellitus, [5] [6] [7] less is known about hypoglycemia in patients with type 2 diabetes mellitus. The Diabetes Control and Complications Trial (DCCT) found a 3-fold greater incidence of severe hypoglycemia in a group of patients with type 1 diabetes undergoing intensive treatment compared with those treated less aggressively. 8 In contrast, the feasibility trial of the Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM) showed an increase in mild and moderate, but not severe, hypoglycemia in patients undergoing intensive treatment, 9 whereas the Kumamoto study showed no increase in mild or severe episodes in patients with type 2 diabetes undergoing intensive treatment compared with those undergoing less intensive treatment. 10 Although the United Kingdom Prospective Diabetes Study (UKPDS) showed an increase in hypoglycemia in patients with type 2 diabetes assigned to the intensive protocol arm, it was largely a study of monotherapy, and many patients had elevated glucose levels. 11 While these studies have assessed hypoglycemia in controlled research settings, there is little information on the frequency of hypoglycemia in typical clinical practice settings. Despite the adverse events associated with hypoglycemia and the potential of fear of these events to limit the use of intensive diabetes therapy, few studies have examined the risk factors for hypoglycemia in patients with type 2 diabetes. Moreover, even less is known about hypoglycemia in minority populations with low literacy levels and high rates of poverty, where tight glycemic control might be more difficult to attain. Therefore, we conducted a cross-sectional study to assess the prevalence of hypoglycemia and its associated risk factors in urban, predominantly African American patients with type 2 diabetes who were treated in a specialized diabetes clinic.
RESULTS
A total of 2279 patients had visits during the study period. Of these, 1022 patients (44.8%) had only a baseline visit and therefore were not included in the study. Patients who had only a baseline visit were not significantly different from those with baseline and follow-up visits, except that they were slightly younger (59.4 vs 61.0 years; P=.002) and had slightly lower fasting plasma glucose values (154 vs 168 mg/dL [8.6 vs 9.3 mmol/L]; P=.01). There was no difference in the prevalence of hypoglycemia between the groups at the baseline visit. Of the 1257 patients with a baseline and a follow-up visit, 202 (16.1%)
METHODS AND RESEARCH DESIGN

SETTING
The study was conducted at the Diabetes Clinic of the Grady Health System, Inc, Atlanta, Ga. The clinic serves a predominantly African American population and provides care for approximately 900 new and 5000 returning patients each year. Plasma glucose level is measured at each visit, and glycosylated hemoglobin (HbA 1c ) level is determined onsite every 2 to 3 months. 12 Patients are initially examined by a nurse provider who provides diabetes education and makes recommendations for changes in therapy. Patients then undergo reevaluation by an endocrinologist who makes final treatment decisions. The clinic management protocol emphasizes lifestyle modification and an attempt to reduce the use of pharmacologic agents during the first 2 months after initial presentation. If adequate glycemic control is not attained after 2 months, pharmacologic therapy is instituted (or increased), and the goal of near normoglycemia is pursued aggressively. Pharmacologic therapy is advanced using a stepped-care approach, beginning with a single oral agent (long-acting glipizide, glyburide, or metformin), and then progressing to combination oral agents, oral agents plus bedtime insulin, and finally multiple-dose insulin regimens. The goal for glycemic control is HbA 1c level of less than 7.0%.
DESIGN
We examined patient visits from April 1 through October 31, 1999. Patients were included in the analysis if they had received a diagnosis of type 2 diabetes mellitus (by clinical criteria described previously 13 ), had been followed up in the Diabetes Clinic for at least 2 months (to avoid the period of deintensification of therapy), and had had at least 2 visits during the study period (baseline and study follow-up visits). Data from the baseline visit were collected to allow hypoglycemia at baseline to be assessed as a contributing factor to hypoglycemia at follow-up. The prevalence of hypoglycemia and other information presented in the results are based on data collected at the follow-up visit.
Data from every patient visit at the Grady Diabetes Clinic are entered into a computerized registry. These data include information on demographics, laboratory test values, current diabetes therapy, and any changes in therapy made at the visit. Answers to the following questions about hypoglycemia are also entered into the database: (1) How many times was your blood glucose level low since the last visit? (2) What was the lowest home glucose monitoring value obtained during these episodes? (3) Were there symptoms associated with these episodes? and (4) How many times did you need help from someone else to treat your low blood glucose level? Hypoglycemia was thus assessed at baseline and follow-up visits.
DEFINITION OF HYPOGLYCEMIA
For purposes of the analysis, mild hypoglycemia was defined as patient report of typical symptoms of hypoglycemia (eg, sweating, tremulousness, hunger, and/or dizziness) that were relieved by eating, or patient report of home glucose monitoring values of less than 60 mg/dL (Ͻ3.3 mmol/L). The cutoff blood glucose level of 60 mg/dL (3.3 mmol/L) was selected to define biochemical hypoglycemia because it is the approximate level at which counterregulatory systems are normally activated and nondiabetic individuals may begin to experience neuroglycopenic and adrenergic symptoms characteristic of hypoglycemia. [14] [15] [16] [17] To estimate the prevalence of biochemical hypoglycemia that would have been obtained if all patients had monitored their capillary blood glucose level during reported symptoms, the number of patients reporting blood glucose levels of less than 60 mg/dL (Ͻ3.3 mmol/L) during symptoms was divided by the number of patients reporting any glucose measurement during symptoms. This proportion was then multiplied by the total prevalence of reported hypoglycemic symptoms to yield an estimated prevalence of biochemical hypoglycemia. Severe hypoglycemia was defined as loss of consciousness or other major alteration of mental status caused by hypoglycemia that required the assistance of another person to treat the condition.
At clinic visits, plasma glucose levels were measured using the glucose oxidase method. We measured HbA 1c level using a turbidimetric immunoinhibition assay (reference range, 3.5%-6.0%) (Roche, Basel, Switzerland).
ANALYSIS
Statistical analysis was conducted using commercially available software (Statview 5.0; SAS Institute Inc, Cary, NC). We used analysis of variance and unpaired 2-tailed t tests to compare means between subgroups of patients and 2 analysis to compare frequency of events between groups. We performed univariate and multivariate logistic regression to determine clinical predictors of hypoglycemia. PϽ.05 was considered significant. had incomplete hypoglycemia data and were excluded. Compared with those who were included in the study, these patients had shorter duration of diabetes (9.4 
01).
A total of 1055 patients were included in the study. Data on patient demographics, glycemic control, and distribution of type of diabetes therapy are shown in Table 1 and Table 2 . Patients were predominantly female and nearly all were African American. Patients had an average age of 61 years, average body mass index (BMI; calculated as weight in kilograms divided by the square of height in meters) of 33, average fasting plasma glucose level of 152 mg/dL (8.4 mmol/L), and average HbA 1c level of 7.6%. Average HbA 1c level was significantly lower in patients whose diabetes was managed by means of diet alone (6.0%) compared with those managed by means of oral agents alone (7.0%) or insulin (8.1%) (PϽ.001). Most patients (92.7%) were treated with some form of pharmacologic therapy, and 60.0% were treated with insulin (alone or in combination with oral hypoglycemic agents). Long-acting glipizide accounted for 85.6% (326/381) of sulfonylurea use, glyburide for 14.2% (54/381), and glimepiride for 0.3% (1/381). Patients had been observed in the diabetes clinic for an average of 6.5 years, and mean (± SEM) length of time between study visits was 89±1 days.
At the follow-up visit, 258 patients (24.5%) reported at least 1 episode of hypoglycemic symptoms or blood glucose level of less than 60 mg/dL (3.3 mmol/L). Prevalence of any hypoglycemic episode varied with type of therapy (Figure 1 ). Patients reporting hypoglycemia included 9 (11.8%) of 76 patients treated with diet therapy alone; 56 (16.2%) of 346 patients treated with oral agents alone (sulfonylurea, metformin, or sulfonylurea plus metformin); and 193 (30.5%) of 633 patients treated with any insulin (PϽ.001 for trend).
There was no significant difference in prevalence of hypoglycemia between patients treated with sulfonylureas or metformin (15 Results of capillary home blood glucose monitoring values at the time of reported hypoglycemia were obtained in 46.1% of patients. Those who reported monitoring of capillary blood glucose levels during hypoglycemia were slightly older (61 vs 58 years; P=.04) and had lower HbA 1c levels (7.1% vs 7.7%; P=.01) than those who did not, but otherwise there were no significant differences between the 2 groups. There was also no significant difference in the proportion of patients reporting a blood glucose level measurement during hypoglycemic symptoms among those treated with diet alone Univariate logistic regression demonstrated that patients treated with insulin were more likely to report hypoglycemia than patients in other treatment groups (P=.001). Similarly, patients who reported any hypoglycemia at the baseline visit were more likely to report hypoglycemia at the follow-up visit (PϽ.001). In addition, fasting plasma glucose level at the time of the follow-up visit and being in the highest age quartile (age Ͼ70 years) were negatively correlated with any hypoglycemia (PϽ.001 and P=.03, respectively). Race, sex, duration of diabetes, BMI, and follow-up HbA 1c level were not predictors of hypoglycemia by univariate analysis. We also performed multiple logistic regression analysis, which showed that lower follow-up HbA 1c level (P=.006), use of any insulin therapy (P =.005), younger age (P=.04), and report of hypoglycemia at the baseline visit (PϽ.001) were all independent predictors of any hypoglycemia at the follow-up visit (Table 3) . Race, sex, duration of diabetes, BMI, and whether diabetes medication therapy was increased at the baseline visit did not predispose to hypoglycemia. Figure 3 shows the relationship between follow-up HbA 1c values and the prevalence of hypoglycemia in patients receiving different types of diabetes therapy, illustrating the trend toward increasing prevalence of both reported and estimated biochemical hypoglycemia with decreasing HbA 1c level.
Severe hypoglycemia was rare and was reported by only 5 patients (0.5%) at the follow-up visits studied ( Table 4) . Patients 1 and 2 suffered loss of consciousness and required transport to the emergency department by emergency medical services (EMS). Patients 3 and 4 were taken to the emergency department by EMS but did not lose consciousness, and patient 5 was treated at home by EMS without loss of consciousness. Age, sex, race, diabetes duration, BMI, follow-up fasting plasma glucose level, follow-up HbA 1c level, type of diabetes therapy, hypoglycemia at the baseline visit, and whether diabetes medication therapy was increased at the baseline visit were not significant predictors of severe hypoglycemia by univariate or multivariate logistic regression.
COMMENT
In this cross-sectional study, we found a high prevalence of any form of reported hypoglycemia in an urban African American population with type 2 diabetes (24.5%), but a low prevalence of severe hypoglycemia (0.5%). As expected, the prevalence of any hypoglycemia was dependent on type of diabetes therapy. Patients receiving triple therapy had the highest prevalence, followed by those receiving insulin therapy alone or with a single oral agent, those receiving oral hypoglycemic agents alone, and those receiving diet therapy alone. It is not clear why those patients receiving triple therapy had such a high prevalence of hypoglycemia. Although mean HbA 1c level for the group was not unusually low (7.4%), it may be that these patients represent a group whose diabetes is more difficult to manage. In all treatment groups, the prevalence of any hypoglycemia tended to increase as HbA 1c level decreased. The highest prevalence was seen in patients receiving insulin therapy who had an HbA 1c level of less than 7.0%. Surprisingly, 9 (11.8%) of the 76 patients treated with diet alone reported some hypoglycemic symptoms, although only 1 patient reported biochemical hypoglycemia. Measurement error may explain the apparent biochemical hypoglycemia in the single patient reporting a blood glucose level of 42 mg/dL (2.3 mmol/L) during symptoms, as such low glucose levels were not reported by this patient at subsequent visits. It is possible that the hypoglycemia-like symptoms reported by some diet-treated patients were unrelated to low blood glucose levels and were, instead, nonspecific symptoms, perhaps related to hunger or anxiety. All patients who attend the Grady Diabetes Clinic are instructed about symptoms of hypoglycemia, including patients treated with diet. In addition, 47 (61.8%) of the 76 patients treated with diet alone at the time of the study had previously been treated with pharmacologic agents and might have experienced hypoglycemia before. Pohl et al 18 studied nondiabetic subjects who underwent insulin-induced hypoglycemia and then were told they were to receive a second insulin injection but were actually given isotonic sodium chloride solution; such subjects reported more neuroglycopenic symptoms than did those who had been told they were to receive a second injection of isotonic sodium chloride solution. A similar phenomenon of expectant hypoglycemia might occur in diettreated patients who are warned about hypoglycemia, particularly those who had been receiving pharmacologic therapy in the past.
Another interesting finding was that older age did not predispose patients to hypoglycemia in our population, although previous reports have suggested that older age is associated with hypoglycemia. 19, 20 Although older patients in our study were less likely to receive insulin therapy (potentially making their risk for hypoglycemia lower), they also had lower average HbA 1c levels (potentially making their risk higher). Several factors may contribute to lower prevalence of hypoglycemia in older patients. First, activity levels in the elderly are likely to be lower than those in younger patients, making exerciseassociated hypoglycemia less likely. Second, eating habits may be more regular in the elderly, so that missed meals causing hypoglycemia are less of a problem. Older patients may also have atypical symptoms 21 or be less symptomatic during mild hypoglycemia, and therefore not report as many episodes. Nevertheless, as life expectancy increases, older patients should benefit more from good glycemic control, and fear of hypoglycemia should not discourage attempts at achieving American Diabetes Association goals in the elderly.
The small number of patients with severe hypoglycemia made it difficult to establish significant predic- tors by means of logistic regression analysis. However, examination of the patients' characteristics (Table 4) showed that severe hypoglycemia only occurred in patients who were treated with insulin and that duration of diabetes was longer than 15 years in 4 of the 5 patients. None of the patients was receiving a particularly high dose of insulin (all Ͻ0.70 U/kg per day). Although all of these patients were overweight (BMI Ͼ25), it is possible that insulin resistance plays a relatively minor role in their disease and that they may have more beta-cell dysfunction than do other patients with type 2 diabetes in our population. Our results indicate that severe hypoglycemia occurs in patients with type 2 diabetes, but it is uncommon and it is difficult to predict which patients are at risk solely on the basis of clinical criteria. An exaggerated fear of severe hypoglycemia should not be the limiting factor in achieving good glycemic control in patients with type 2 diabetes. Because of population differences and the crosssectional design of this study, our results cannot be compared directly with those of the UKPDS or DCCT. However, some trends were similar. As in the UKPDS, we found that any hypoglycemia was more common in insulintreated patients than in those treated with oral hypoglycemic agents or diet alone. 11 We also found a low prevalence of severe hypoglycemia at the visits studied, but, unlike the UKPDS, all episodes in our study were associated with insulin therapy. The DCCT found that the prevalence of severe hypoglycemia increased as HbA 1c levels fell and that patients with previous episodes of hypoglycemia were more likely to experience hypoglycemia in the future. 22 In our study, multiple logistic regression also showed lower HbA 1c levels and a report of hypoglycemia at the baseline visit to be independent predictors of any hypoglycemia. Our results are consistent with those of Hayward et al, 23 who found that 38% of patients treated with insulin reported hypoglycemic symptoms more than once a month. Jennings et al 24 examined the prevalence of hypoglycemia in patients treated with oral hypoglycemic agents and found that 20% of patients treated with sulfonylureas had symptoms of hypoglycemia during the previous 6 months, but none of 16 patients receiving metformin alone had symptoms. Although 3 (8.6%) of our 32 patients treated with metformin alone reported hypoglycemic symptoms, this rate was comparable to the prevalence in diet-treated patients. Accordingly, our results also support those of Jennings et al, 24 although patients treated with oral agents in our study had an average HbA 1c level of 7.0% vs 11.0% in theirs (reference range, 6%-8%).
Limitations of our study include its cross-sectional design, which prevents an exact calculation of incidence of hypoglycemia and therefore prohibits direct comparison of the results of our study with those of the UKPDS, 11 VA CSDM, 9 or DCCT. 8 In addition, the data rely on patients' abilities to remember and interpret symptoms as a consequence of low blood glucose levels. Consistent with earlier studies and routine practice, which rely on patient self-reports to make clinical decisions, our results reflect information that is clinically relevant and available to most practitioners. Another limitation may be that most of our patients are urban and African American. Although we do not know whether our results are generalizable to other populations, the findings suggest that hypoglycemia is not a major problem in a population with an average HbA 1c level of 7.6%, despite the limitations of poverty and low literacy levels. 13, 25 However, we consider it unlikely that African Americans are more or less prone to hypoglycemia than are other ethnic groups.
CONCLUSIONS
Hypoglycemia can be an important limiting factor in the treatment of patients with type 2 diabetes. Our results suggest that aggressive management aimed at achieving near-normal glucose levels is associated with increased risk for hypoglycemia as HbA 1c level approaches the American Diabetes Association goal of less than 7.0%. However, fear of severe hypoglycemia should not deter the attempt to achieve tight glycemic control. Those patients who are younger or have a lower HbA 1c level may be at higher risk for hypoglycemia and should be encouraged to be more diligent about meal planning, home monitoring of glucose levels, and symptom awareness. Finally, older patients may not be particularly prone to hypoglycemia and therefore should not be disqualified from intensive control of blood glucose level on the basis of risk for hypoglycemia alone.
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